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The management of heart rhythm as part of the treatment
of atrial fibrillation (AF) has been the subject of intensive
investigation over the past two decades. Until recently, most
physicians have believed that the initial approach to rhythm
management should give primary consideration to restora-
tion and maintenance of sinus rhythm (SR) (1). The
potential benefits of restoration and maintenance of SR
include, among others, relief of symptoms, improved exer-
cise tolerance, prevention of stroke, less need for anticoag-
ulant therapy, improved hemodynamic function, and pre-
vention of tachycardia-induced cardiomyopathy (2). The
negative aspects of this approach include the rather poor
efficacy of the antiarrhythmic drugs (3) and the potential of
these drugs to cause adverse effects, including death (4). The
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balance between the benefit and risk of restoration and
maintenance of SR, primarily with drug therapy, until this
point in time has not been rigorously tested but rather
assumed. Accordingly, the past two decades of research on
pharmacologic rhythm management for AF have focused on
the capability of restoring and maintaining SR, regardless of
the recognized limitations, with the expectation that benefit
would accrue from this approach. However, research on
rhythm management for AF has evolved more recently,
partly because of the demonstration of the remarkable
efficacy of anticoagulation for the prevention of stroke in AF
in the 1980s and 1990s (5), partly because of the limitations
of drug therapy (3,4), and partly because of the recognition
of the limitations of surrogate end points in trials of
arrhythmia management (6). First, there has been the
emergence of a number of nonpharmacologic therapies (7).
Second, there has been an attempt to refocus on measuring
clinical end points in studies of rhythm management of AF,
rather than assuming SR restoration and maintenance is
beneficial (6). And third, there has been a renewed interest
in the strategy of heart rate (HR) control as a primary
rhythm treatment modality as part of the management of
AF, rather than using it only as a second choice or a
temporary measure (8). In this issue of the Journal, two
articles address important aspects of this last point (9,10).
The STAF trial. Strategies of Treatment of Atrial Fibril-
lation (STAF) is the fourth randomized trial to be published
comparing the strategy of rhythm control to the strategy of
rate control for the rhythm management portion of the
treatment of AF. It was preceded by the Pharmacological
Intervention in Atrial Fibrillation (PIAF) trial (11) and was
concurrent with Atrial Fibrillation Follow-up Investigation
of Rhythm Management (AFFIRM) (12) and RAte Con-
trol Versus Electrical Cardioversion for Persistent Atrial
Fibrillation (RACE) (13). The primary end point of PIAF
was the proportion of patients with improvement in symp-
toms (11). The primary end point of STAF was a composite
including death, cardiopulmonary resuscitation, cerebrovas-
cular event, or systemic embolus (9). RAte Control Versus
Electrical Cardioversion for Persistent Atrial Fibrillation
used a somewhat similar composite end point (13). The
primary end point in AFFIRM was total mortality (12).
However, secondary end points in each trial are comple-
mentary to the primary end points of the others. Three of
the four trials also reported on quality of life and all four
reported on hospitalizations (9,11–13). None of the studies
reported any advantage for the rhythm control strategy.
In STAF, no differences were found between the two
treatment strategies with respect to the primary end point.
An important aspect of the findings in STAF was that the
proportion of patients assigned to the rhythm control
strategy in whom SR could be maintained was low, only
23% after three years. Furthermore, at the time the primary
events were detected in STAF patients in both treatment
strategies, only one out of 19 was in SR. This last observa-
tion might lead one to conclude that if only SR could be
successfully maintained, it would be a superior treatment to
HR control. The STAF investigators, quite correctly, did
not reach that conclusion. There are several reasons that
conclusion remains a hypothesis to be tested. First, it is
important to point out that the rhythm at the moment the
event occurred could not be known with certainty in many
of these patients. The first rhythm recorded when the
patient receives medical attention is not necessarily the one
present at the time of the event or immediately before the
event. Second, in the AFFIRM trial, which included some
patients (30%) with paroxysmal AF, investigators were
able to maintain SR in 60% of their patients over five
years, and that trial also showed no advantage of the rhythm
control strategy (12). Third, ease of maintenance of SR may
itself be an independent predictor of a favorable outcome.
This last point is illustrated in the dofetilide-AF results
demonstrating a favorable outcome with SR versus AF in
both the placebo and dofetilide-treated arms, but no survival
advantage attributable to dofetilide (14). Finally, the poten-
tial adverse effects of the treatments for restoration and
maintenance of SR cannot be ignored as a source of
morbidity and mortality in the treatment of AF. Indeed,
AFFIRM and RACE reported more frequent adverse drug
effects in the rhythm control approach (12,13).
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It is also interesting to note a slight excess of stroke/
systemic embolus in the rhythm control strategy compared
with the rate control strategy in STAF. A similar observa-
tion was noted in AFFIRM (12) and RACE (13), but in no
study was the difference significant. To some extent the use
of anticoagulants in all trials was different in the two
treatment strategies (greater anticoagulant use in the rate
control arm), because of the belief by many that when SR is
restored and maintained for at least one month, anticoagu-
lation can be discontinued (2). Thus, it is tempting to
attribute the observation of such a difference in thrombo-
embolic events to the difference in anticoagulant use in the
two treatment strategies. Indeed, this may be the major
portion of the explanation. However, one could also hy-
pothesize that alternating between AF and SR in partially
successful rhythm management may be more likely to eject
emboli from the heart than continuous AF. Whatever the
explanation, it should be stressed that because of these
uncertainties, anticoagulation should rarely be discontinued
in high-risk patients (those with stroke risk factors) or in the
persistent form of AF, even when the treating physician
feels that SR has been restored and maintained. This is a
new finding and seems contrary to current guideline recom-
mendations (2), although it must be recognized that the
guidelines are ambiguous on this point.
Although STAF did not report on quality-of-life mea-
sures, all three of the other trials found no difference in
quality of life between the two treatment strategies. All four
trials (9,11–13) did find that there are significantly more
hospitalizations using the rhythm control strategy. Hospi-
talization has an important implication with respect to cost
of the strategy. Although none of these studies has yet
produced a published formal cost analysis, if it is indeed true
that the cost of the rhythm control strategy is greater and
there are no advantages attributable to it, then one could
easily infer that the rate control strategy is the preferred
initial approach, on the basis of cost-effectiveness, in pa-
tients such as those enrolled in the trials. At the very least,
one is led to conclude that the rate control strategy should
be considered as a primary therapy, not a second choice
when rhythm control fails.
Given the strength and consistency of this emerging
evidence, an important consideration is whether or not the
results of these four trials apply to all patients with AF. To
answer that question, one must look carefully at the type of
patients enrolled in them, the therapies used, and any
subgroup analyses available. In all four studies (9,11–13),
patients were predominantly the elderly with persistent AF
(2). Furthermore, only a minority had extensive structural
heart disease. Finally, it is not possible from the available
information to determine the reasons that eligible patients
were not enrolled in the trials.
A number of potential biases arise in the enrollment of
patients in most clinical trials. One of the strongest physi-
cian biases in the treatment of AF is that highly symptom-
atic patients need to be treated with the rhythm control
strategy (1,15). To the extent that such a bias meant highly
symptomatic patients were not enrolled in these trials
comparing the rate control strategy to the rhythm control
strategy, the results may not apply to highly symptomatic
patients. However, because the final mode of therapy for the
highly symptomatic patient is often the ablate and pace
approach (16), it should be recalled that the ablate and pace
approach is very effective for highly symptomatic patients
and is part of the rate control strategy (17). There are
virtually no young patients with highly symptomatic parox-
ysmal AF and minimal or no heart disease in these four
trials. Therefore, the results do not apply to such patients,
who are the primary type of patient currently having a
pulmonary vein radiofrequency ablative procedure (18). It
must also be recognized that these trials compared predom-
inantly pharmacologic therapies. Perhaps greater use of
nonpharmacologic therapies might have produced more
favorable (or less favorable) results with respect to the
rhythm control strategy. Finally, the AFFIRM trial is the
only trial that is large enough to do subgroup analyses in
order to generate hypotheses about enrolled patients in
whom the rhythm control strategy might be preferable. The
data do not reveal an advantage of the rhythm control
strategy with respect to mortality for any of the prespecified
subgroups in that study, although the point estimate of the
hazard ratio is less than one for two groups: younger
patients and those with congestive heart failure (12).
Clearly, more data are needed on groups of patients and
therapies underrepresented in these trials. In the meantime,
the presumed superiority of the rhythm control approach
should remain a presumption in groups that were not tested.
The Australian Intervention Randomized Control of
Rate in Atrial Fibrillation Trial (AIRCRAFT). Now
that the rate control strategy has been elevated to the
position of a primary treatment for AF, we need to know a
lot more about it than we do at the present time. Research
on the rate control strategy is currently sparse, to say the
least. It is useful to dissect out some of the aspects of HR
control in the management of AF before a discussion of the
Australian Intervention Randomized Control of Rate in
Atrial Fibrillation Trial (AIRCRAFT). Many understand
effective HR control to be the prevention of excessive HRs.
Some even understand that excessive HRs need to be
assessed during rest and activity. However, fewer have
acknowledged that good rate control also encompasses the
absence of chronotropic incompetence and some effort at
regularization of the HR. Finally, we need to identify
patient groups that will benefit the most from the best HR
control therapies that we can deliver. The AIRCRAFT (10)
addresses this last question.
Few data exists about the first few issues in rate control.
Some data exist about the appropriateness of a resting HR
80/min (19). To my knowledge, no data exists that
objectively defines appropriate upper limits of HR during
activity or data that objectively defines chronotropic incom-
petence for patients with AF. There are data that have
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highlighted the importance of regularity of the heartbeat in
patients with AF (20). Most physicians would probably
acknowledge that with respect to all these aspects of “good”
HR control, the ablate and pace approach currently repre-
sents our best attempt at HR control. The AIRCRAFT
examines this approach in a particular subset of patients that
has not previously been examined.
The AIRCRAFT enrolled patients with few symptoms
and well-preserved ventricular function who were already
judged to have adequate pharmacologic HR control (10).
Co-primary end points were left ventricular function as-
sessed by echocardiography and functional capacity on a
graded treadmill test. Secondary end points included HR
control itself and quality of life assessed by questionnaire.
There were no differences between the effect of the two
treatments on the ventricular systolic function and the
duration of exercise during the treadmill tests. However,
peak HRs and quality of life were better in the ablate and
pace treatment group. There are some issues to be noted,
however, with respect to these findings. The first is that a lot
of patients assigned to the ablate and pace approach (15 of
49) did not receive that treatment, primarily because they
were already doing well. If one considers that a major
objective of treating AF is to relieve symptoms, it is not too
surprising that patients who are already feeling quite well
would ultimately not want to accept a relatively invasive
therapy. Furthermore, one interpretation of the noted im-
provement in quality of life is that perhaps these patients did
not feel as well as they thought, and they indeed felt better
after the ablate and pace treatment. It is important to note,
however, that the therapies could not be blinded for the two
approaches used in the AIRCRAFT. Accordingly, an im-
provement in quality of life in the ablate and pace treatment
arm must be viewed with skepticism.
The authors did not feel that the lack of blinding could
explain their findings (10). However, a useful comparison is
two recent trials of pacing for vasovagal syncope. In the first
trial, patients were randomized to a pacemaker or no
pacemaker (open-label) and the point estimate for the
relative risk reduction of syncopal episodes was highly
significant and 85% (21). However, when the same
investigators repeated the study implanting a pacemaker in
all subjects and randomizing whether or not pacing was “on”
or “off” (blinded), the relative risk reduction was not
significant and closer to 25% (unpublished data, presented
as a Late Breaking Clinical Trial at NASPE 2002). There-
fore, implanting a pacemaker can indeed have a powerful
placebo effect. Finally, a lower peak HR with exercise is a
surrogate end point and in itself is less meaningful (7).
With respect to their primary end point, the AIRCRAFT
investigators recognized the importance of baseline left
ventricular function and stratified on the basis of left
ventricular ejection fraction 0.45 and 0.45. However,
the range of left ventricular ejection fractions available for
the analysis was limited. Observational studies had already
suggested that ventricular function would only be improved
with this treatment modality when ventricular systolic
function was already substantially reduced at enrollment
(16). Thus, it is not too surprising that no difference was
noted between apparently good pharmacologic HR control
and the ablate and pace approach in this population with
well-preserved systolic function. Thus, in summary the
AIRCRAFT is a negative trial, showing no benefit of the
ablate and pace approach in this patient subgroup. The
authors correctly conclude that the ablate and pace approach
is not indicated for this purpose.
Summary. What is the simple lesson from these two quite
different studies? It seems obvious that in the two situations
explored in these two trials, the main finding is that for
many patients “less is more.” In the case of the STAF trial,
the implication is that extensive effort to restore and
maintain SR is not warranted for many elderly patients with
persistent AF. In the case of the AIRCRAFT, the ablate
and pace approach is not warranted for improvement of
ventricular function unless ventricular function is already
reduced, and it cannot improve symptoms when pharma-
cologic rate control is well tolerated and the patient is doing
well with respect to symptoms.
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